𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment of hypercholesterolemia with the HMG CoA reductase inhibitor, simvastatin

✍ Scribed by GMB Berger; AD Marais; HC Seftel; SG Baker; D Mendelsohn; NH Welsh; BI Joffe


Publisher
Springer US
Year
1989
Tongue
English
Weight
767 KB
Volume
3
Category
Article
ISSN
0920-3206

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Simvastatin, a competitive inhibitor of
✍ William C. Duane; Donald B. Hunninghake; Martin L. Freeman; Pete A. Pooler; Lind πŸ“‚ Article πŸ“… 1988 πŸ› John Wiley and Sons 🌐 English βš– 495 KB πŸ‘ 1 views

We tested the possibility that simvastatin, a competitive inhibitor of HMG-CoA reductase related to mevinolin, might alter cholesterol saturation of gallbladder bile. Ten patients with Type IIa or IIb hypercholesterolemia underwent bile sampling before, and again after, treatment with 20 or 40 mg pe

A New and Efficient Synthesis of the HMG
✍ Murat Acemoglu; Andre Brodbeck; Angel Garcia; Dominique Grimler; Marc Hassel; Be πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 German βš– 147 KB

## Abstract A new synthetic method for the preparation of pitavastatin is described. The approach circumvents various synthetic problems associated with the buildup of the 3,5‐dihydroxy‐C~7~ acid side chain of HMG‐CoA reductase inhibitors (statins). The use of the C~6~‐amide derivative **5** instea

A New and Efficient Synthesis of the HMG
✍ Murat Acemoglu; Andre Brodbeck; Angel Garcia; Dominique Grimler; Marc Hassel; Be πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 German βš– 23 KB

On p. 1074, in Scheme 3, the correct formula of NK-104 should be as follows: 2) On p. 1077, line 16 should read as follows: (390 ml) was cooled to Γ€ 788, and 1.6m BuLi in hexane (374.4 g, 881 mmol) was added under 3) On p. 1078, line 15 should read as follows: As HPLC revealed the presence of mor

Therapeutic efficacy of the HMG-CoA-redu
✍ H. Saxenhofer; P. Weidmann; W. F. Riesen; C. Beretta-Piccoli; C. Fragiacomo; R. πŸ“‚ Article πŸ“… 1990 πŸ› Springer 🌐 English βš– 533 KB

The efficacy and safety of the HMG-CoA-reductase inhibitor pravastatin was assessed in a double-blind, placebo controlled study. Thirty patients (51 y) with hyperlipoproteinaemia Type IIa (N = 22) or IIb (N = 8) received for 16 weeks either pravastatin 5 mg b.d. for 8 weeks followed by 10 mg b.d. fo